Results 21 to 30 of about 6,568,172 (215)

Insights into the inhibitory activities of neolignans and diarylnonanoid derivatives from nutmeg (Myristica fragrans Houtt.) seeds on soluble epoxide hydrolase using in vitro and in silico approaches

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Two new neolignans, myrifralignans F–G (14 and 18), four new diarylnonanoid derivatives, myrifragranones A–D (21–24), and 18 known compounds were isolated and structurally elucidated from nutmeg (Myristica fragrans Houtt.) seeds.
Vu Thi Oanh, Nguyen Viet Phong, Byung Sun Min, Seo Young Yang, Jeong Ah Kim   +4 more
doaj   +1 more source

Digoxin + Cyclosporine - contextualized potential drug-drug interaction clinical algorithm

, 2020
An algorithm developed for research purposes that summarizes the potential drug-drug interaction between digoxin and cyclosporine. The information is not advice, and should not be treated as such.
Contributors to the A Minimum Representation of Potential Drug-Drug Interaction Knowledge and Evidence - Technical and User-centered Foundation Specification
core   +1 more source

Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates

Journal of Advanced Pharmaceutical Technology & Research, 2021
The majority of the antipsychotic drugs are also known to interact with other co-administered drugs. Drug–drug interaction (DDI) reports among patients receiving antipsychotic medications are common.
Haneen A. R. Aburamadan, Sathvik Belagodu Sridhar, Talaat Matar Tadross   +2 more
doaj   +1 more source

Quantitative estimate of protein-protein interaction targeting drug-likeness [PDF]

, 2021
The quantification of drug-likeness is very useful for screening drug candidates. The quantitative estimate of drug-likeness (QED) is the most commonly used quantitative drug efficacy assessment method proposed by Bickerton et al.
Takatsugu, Kosugi, Masahito, Ohue
core   +1 more source

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications

Current Therapeutic Research
Objective: This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.
Jingjing Yu, MD, PhD, Sophie Argon, PharmD, Katie Owens, BPharm, PhD, Yan Wang, MS, Isabelle Ragueneau-Majlessi, MD, MS   +4 more
doaj   +1 more source

An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021

Clinical and Translational Science, 2023
Kratom is a widely used Asian botanical that has gained popularity in the United States due to a perception that it can treat pain, anxiety, and opioid withdrawal symptoms. The American Kratom Association estimates 10–16 million people use kratom. Kratom‐
Xiaotong Li, Patrick Ndungu, Sanya B. Taneja, Maryann R. Chapin, Susan B. Egbert, Krishi Akenapalli, Mary F. Paine, Sandra L. Kane‐Gill, Richard D. Boyce   +8 more
doaj   +1 more source

Tamoxifen-Paroxetine - contextualized potential drug-drug interaction clinical algorithm

, 2018
An algorithm developed for research purposes that summarizes the potential drug-drug interaction between tamoxifen and paroxetine. The information is not advice, and should not be treated as such.
Contributors to the A Minimum Representation of Potential Drug-Drug Interaction Knowledge and Evidence - Technical and User-centered Foundation Specification
core   +1 more source

Warfarin - Sulfamethoxazole-trimethoprim - contextualized potential drug-drug interaction clinical algorithm

, 2018
An algorithm developed for research purposes that summarizes the potential drug-drug interaction between Warfarin - Sulfamethoxazole-trimethoprim. The information is not advice, and should not be treated as such.
Contributors to the A Minimum Representation of Potential Drug-Drug Interaction Knowledge and Evidence - Technical and User-centered Foundation Specification
core   +1 more source

Prediction of human drug clearance and anticipation of clinical drug-drug interaction potential from in vitro drug transport studies [PDF]

, 2014
A major concern in drug development is the characterization of new molecular entities (NMEs) with respect to their safety and efficacy. Both factors are determined by the drug’s exposure within the body which itself is affected by drug clearance ...
Kunze, Annett
core   +1 more source

Drug-gene interaction and druggable genes associated with each GO process in each ML cluster.

, 2023
Drug-gene interaction and druggable genes associated with each GO process in each ML cluster.
Sudhanshu Shukla (408600), S. R. M. Prasanna (13236801), Seema Khadirnaikar (9227318)   +2 more
core   +1 more source